BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 25382188)

  • 1. A novel trial of topotecan, ifosfamide, and carboplatin (TIC) in children with recurrent solid tumors.
    Radhakrishnan K; Lee A; Harrison LA; Morris E; Shen V; Gates L; Wells RJ; Wolff JE; Garvin JH; Cairo MS
    Pediatr Blood Cancer; 2015 Feb; 62(2):274-278. PubMed ID: 25382188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of pediatric recurrent and refractory malignant solid tumors following ifosfamide/carboplatin/etoposide (ICE): A phase II study in a pediatric oncology centre in Brazil.
    Loss JF; Santos PP; Leone LD; Brunetto AL
    Pediatr Blood Cancer; 2004 Feb; 42(2):139-44. PubMed ID: 14752877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
    Miller AA; Al Omari A; Murry DJ; Case D
    Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: enhanced hematological responses but a high incidence of grade III/IV constitutional toxicities.
    Bracho F; Krailo MD; Shen V; Bergeron S; Davenport V; Liu-Mares W; Blazar BR; Panoskaltsis-Mortari A; van de Ven C; Secola R; Ames MM; Reid JM; Reaman GH; Cairo MS
    Clin Cancer Res; 2001 Jan; 7(1):58-67. PubMed ID: 11205919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of ifosfamide, carboplatin, and etoposide in children with solid tumors.
    Cairo MS
    Semin Oncol; 1995 Jun; 22(3 Suppl 7):23-7. PubMed ID: 7610395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: a Children's Cancer Group report.
    Abu-Ghosh AM; Krailo MD; Goldman SC; Slack RS; Davenport V; Morris E; Laver JH; Reaman GH; Cairo MS
    Ann Oncol; 2002 Mar; 13(3):460-9. PubMed ID: 11996479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
    Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical and pharmacokinetic study of combination chemotherapy with topotecan and ifosfamide in patients with progressive or relapsed solid tumors.
    Schneider CP; Merkel U; Grübner U; Kath R; Höffken K; Hoffmann A
    J Cancer Res Clin Oncol; 2002 Jun; 128(6):313-8. PubMed ID: 12073049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failure of granulocyte-macrophage colony-stimulating factor to reduce febrile neutropenia in children with recurrent solid tumors treated with ifosfamide, carboplatin, and etoposide chemotherapy.
    Marina NM; Shema SJ; Bowman LC; Rodman J; Douglass EC; Furman WL; Pappo A; Santana VM; Hudson M; Meyer WH
    Med Pediatr Oncol; 1994; 23(4):328-34. PubMed ID: 8058003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors.
    Marina NM; Rodman JH; Murry DJ; Shema SJ; Bowman LC; Jones DP; Furman W; Meyer WH; Pratt CB
    J Natl Cancer Inst; 1994 Apr; 86(7):544-8. PubMed ID: 8133538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience.
    Van Winkle P; Angiolillo A; Krailo M; Cheung YK; Anderson B; Davenport V; Reaman G; Cairo MS
    Pediatr Blood Cancer; 2005 Apr; 44(4):338-47. PubMed ID: 15503297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study.
    Cairo MS; Davenport V; Bessmertny O; Goldman SC; Berg SL; Kreissman SG; Laver J; Shen V; Secola R; van de Ven C; Reaman GH
    Br J Haematol; 2005 Jan; 128(1):49-58. PubMed ID: 15606549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
    Griffin TC; Weitzman S; Weinstein H; Chang M; Cairo M; Hutchison R; Shiramizu B; Wiley J; Woods D; Barnich M; Gross TG;
    Pediatr Blood Cancer; 2009 Feb; 52(2):177-81. PubMed ID: 18816698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
    Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
    Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age.
    Donfrancesco A; Jenkner A; Castellano A; Ilari I; Milano GM; De Sio L; Cozza R; Fidani P; Deb G; De Laurentis C; Inserra A; Dominici C
    Acta Paediatr Suppl; 2004 May; 93(445):6-11. PubMed ID: 15176712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme.
    Aoki T; Mizutani T; Nojima K; Takagi T; Okumura R; Yuba Y; Ueba T; Takahashi JA; Miyatake S; Nozaki K; Taki W; Matsutani M
    J Neurosurg; 2010 Jan; 112(1):50-6. PubMed ID: 19538050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer Group.
    Cairo MS; Krailo MD; Weinthal JA; Secola R; Bergeron S; van de Ven C; Blazar BR; Garrison L; Reaman GH
    Cancer; 1998 Oct; 83(7):1449-60. PubMed ID: 9762948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas.
    Zhou P; Liu P; Zhou SY; He XH; Han XH; Qin Y; Yang S; Zhang CG; Gui L; Yao JR; Zhao LY; Zhang SX; Sun Y; Shi YK
    Chin Med J (Engl); 2015 Sep; 128(18):2498-504. PubMed ID: 26365969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of childhood: a Pediatric Oncology Group Phase I/II study.
    Kung FH; Desai SJ; Dickerman JD; Goorin AM; Harris MB; Inoue S; Krischer JP; Murphy SB; Pratt CB; Toledano S
    J Pediatr Hematol Oncol; 1995 Aug; 17(3):265-9. PubMed ID: 7620926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.